Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-09-01

Clinical Trial Update: Study of Trilipix Effects on Lipids and Arteries [Phase 4]

View source ↗

Summary

A Phase 4 trial assessing Trilipix effects on lipids and arterial health in dyslipidemia was terminated, with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Trilipix (fenofibric acid)

Snippet

Sponsor: University of Utah | Conditions: Dyslipidemia | Phase 4 | Status: TERMINATED | Results posted: 2016-09-01